Patents Expiring in December 2045
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | EPINEPHRINE | epinephrine | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 215425-001 | Mar 13, 2025 | RX | Yes | Yes | 12,539,283 | ⤷ Start Trial | Y | ||||
| Madrigal | REZDIFFRA | resmetirom | TABLET;ORAL | 217785-001 | Mar 14, 2024 | RX | Yes | No | 12,377,104 | ⤷ Start Trial | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ||||
| Madrigal | REZDIFFRA | resmetirom | TABLET;ORAL | 217785-002 | Mar 14, 2024 | RX | Yes | No | 12,377,104 | ⤷ Start Trial | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ||||
| Madrigal | REZDIFFRA | resmetirom | TABLET;ORAL | 217785-003 | Mar 14, 2024 | RX | Yes | Yes | 12,377,104 | ⤷ Start Trial | TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS) | ||||
| Axsome | SYMBRAVO | meloxicam; rizatriptan benzoate | TABLET;ORAL | 215431-001 | Jan 30, 2025 | RX | Yes | Yes | 12,544,383 | ⤷ Start Trial | ACUTE TREATMENT OF MIGRAINE | ||||
| Avyxa Holdings | KYXATA | carboplatin | SOLUTION;INTRAVENOUS | 219921-001 | Aug 8, 2025 | DISCN | Yes | No | 12,427,104 | ⤷ Start Trial | Y | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
